Annual report pursuant to Section 13 and 15(d)

Licenses and Collaborations (Details Narrative)

Licenses and Collaborations (Details Narrative) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 06, 2018
Collaboration Agreement [Member] | January 2, 2019 [Member]    
Proceeds from collaborators $ 4,000  
Royalty received on sales $ 156,000  
Emory University [Member]    
License agreement, description On December 6, 2018, we notified Emory University ("Emory") of the termination of our License Agreement with Emory, dated March 7, 2013 (the "License Agreement"). Pursuant to the License Agreement, Emory agreed to add to the Licensed Patents and Licensed Technology Emory's rights to any patent, patent application, invention, or technology application that was based on technology disclosed within three (3) years of March 7, 2013. The License Agreement included payments due to Emory ranging from $40,000 to $500,000 based on successful achievement of certain drug development milestones. Additionally, Cocrystal undertook to make royalty payments at 3.5% of net sales due to Emory with a minimum in year one of $25,000 and increase to $400,000 in year five upon product commercialization.  
Emory University [Member] | License Agreement [Member]    
Due from related party   $ 0
Emory University [Member] | Minimum In One Year [Member]    
Royalty payment $ 25  
Emory University [Member] | Maximum In Five Year [Member]    
Royalty payment $ 400  
Emory University [Member] | Sales Revenue, Net [Member]    
Royalty, percentage 3.50%  
Emory University [Member] | Minimum [Member]    
Payments due to achievement of certain drug development milestones $ 40  
Emory University [Member] | Maximum [Member]    
Payments due to achievement of certain drug development milestones $ 500